Lista de obras - Bruno Paiva - Dominio Público Uruguay

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.

artículo científico publicado en 2012

Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity.

artículo científico publicado en 2018

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

scientific article published on 01 October 2019

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

artículo científico publicado en 2010

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

artículo científico publicado en 2020

Combination of Intra-Articular and Intraosseous Injections of Platelet Rich Plasma for Severe Knee Osteoarthritis: A Pilot Study.

artículo científico publicado en 2016

Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma

artículo científico publicado en 2011

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

artículo científico publicado en 2020

Deficient spindle assembly checkpoint in multiple myeloma

artículo científico publicado en 2011

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

artículo científico publicado en 2017

Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile

artículo científico publicado en 2013

Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction

artículo científico publicado en 2014

Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

artículo científico publicado en 2013

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

artículo científico publicado en 2018

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

artículo científico publicado en 2018

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

artículo científico publicado en 2014

Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy

artículo científico publicado en 2014

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

artículo científico publicado en 2011

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.

artículo científico publicado en 2015

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

artículo científico publicado en 2020

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

artículo científico publicado en 2016

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

artículo científico publicado en 2014

International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

artículo científico publicado en 2020

Is immunotherapy here to stay in multiple myeloma?

artículo científico publicado en 2017

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

artículo científico publicado en 2013

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.

artículo científico publicado en 2016

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

artículo científico publicado en 2016

Modulation of Synovial Fluid-Derived Mesenchymal Stem Cells by Intra-Articular and Intraosseous Platelet Rich Plasma Administration

artículo científico publicado en 2016

Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials

article

Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma

artículo científico publicado en 2014

Origin of Waldenstrom's macroglobulinaemia

artículo científico publicado en 2016

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

artículo científico publicado en 2011

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial

artículo científico publicado en 2020

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.

artículo científico publicado en 2016

Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines

artículo científico publicado en 2014

Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis

artículo científico publicado en 2016

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials

artículo científico publicado en 2018

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

artículo científico publicado en 2014

Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukemia

artículo científico publicado en 2018

Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease

scientific article published on 22 April 2019

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

scientific article published on 23 October 2015

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.

artículo científico publicado en 2017

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.

artículo científico publicado en 2017

The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells

artículo científico publicado en 2011

The cellular origin and malignant transformation of Waldenström macroglobulinemia.

artículo científico publicado en 2015

The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

artículo científico publicado en 2011

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.

artículo científico publicado en 2014

Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

scientific article published on 08 October 2019

Treatment for patients with newly diagnosed multiple myeloma in 2015.

artículo científico

Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients

artículo científico publicado en 2010

miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma

artículo científico publicado en 2020

Lista de obras de Bruno Paiva

Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.

Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity.

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma

Combination of Intra-Articular and Intraosseous Injections of Platelet Rich Plasma for Severe Knee Osteoarthritis: A Pilot Study.

Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Deficient spindle assembly checkpoint in multiple myeloma

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile

Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction

Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.

Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

Is immunotherapy here to stay in multiple myeloma?

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.

Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients

Modulation of Synovial Fluid-Derived Mesenchymal Stem Cells by Intra-Articular and Intraosseous Platelet Rich Plasma Administration

Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials

Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma

Origin of Waldenstrom's macroglobulinaemia

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.

Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines

Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukemia

Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.

The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells

The cellular origin and malignant transformation of Waldenström macroglobulinemia.

The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis

The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.

Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

Treatment for patients with newly diagnosed multiple myeloma in 2015.

Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients

miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma